Featured Research

from universities, journals, and other organizations

Fight against river blindness is successful and inexpensive

Date:
February 1, 2013
Source:
Public Library of Science
Summary:
A relatively inexpensive program set up to combat river blindness has resulted in major health improvements in Africa, shows a new study. The study shows that US $250 million helped cure or prevent the major symptoms of onchocerciasis in millions of people.

A relatively inexpensive program set up to combat river blindness, an infectious disease, has resulted in major health improvements in Africa, shows a study conducted by Erasmus University Medical Center researchers. The study, due to be published January 31 in PLOS Neglected Tropical Diseases, shows that US$250 million helped cure or prevent blindness, skin disease, severe itching, and other symptoms in millions of people. In collaboration with the Management of the African Programme for Onchocerciasis Control (APOC), the researchers calculated the health impact of APOC.

Onchocerciasis, also known as river blindness, is an infectious parasitic disease transmitted by flies that live near fast-flowing rivers. The worm that causes the disease lives in subcutaneous nodules. The bite of the fly passes the worm's larvae from human to human. During their lifetime, people in endemic regions often contract several infections, which accumulate and can lead to blindness. Infected people may suffer from severe itching, leading to insomnia and inability to concentrate. This makes working or going to school difficult. 'This means people are less able to provide for themselves, especially in developing countries,' says Erasmus MC researcher Luc Coffeng. 'It is for a reason that in images of river blindness you often see a blind person moving around holding the end of a stick accompanied by a child holding the other end.'

In 1995, the WHO launched the African Programme for Onchocerciasis Control (APOC) to combat river blindness. APOC has geographically mapped the disease, and has started annual mass treatment with the drug ivermectin in sixteen African countries. Ivermectin kills the larvae in the human and thus prevents transmission of the infection and development of irreversible symptoms, such as blindness. Manufacturer Merck helps by providing ivermectin for as long as needed, free of charge. APOC distributes the drug in an efficient and inexpensive manner through a community-directed approach. Specially trained volunteers operate at the local level; they find out which people are eligible for treatment, and ensure that these people get the drug. This saves time for health professionals, and makes it easier to continue mass treatment in situations of political instability.

In fifteen years' time, APOC has had a major health impact at relatively low cost, according to the researchers. The percentage of people infected with the parasite decreased from 45 to 31 percent among a population of 104 million people. 'Blindness and visual impairment now occur much less frequently in the APOC countries. And the percentage of people suffering from severe itching decreased from 14 to 6 percent,' said Coffeng. The researchers express the impact of the programme in terms of years of healthy life gained: 'This metric expresses our preference for people to live their life in good health rather than in disease. For instance, for every year lived in blindness, we consider 0.6 years of healthy life lost.' The program has already saved a total of eight million healthy years of life, at a cost of about US$250 million. 'Peanuts compared to what we in the Western world are spending on healthcare,' commented Coffeng. 'APOC costs 30 dollars for every year of healthy life gained, while in the Western world we are willing to spend tens of thousands of dollars to achieve this.'

The fight against river blindness is not yet over. The percentage of people carrying infection is expected to decline further, to about 18% in 2015. 'APOC has made tremendous efforts to implement mass treatment in all countries in need. The last countries joined the program only in 2010. Treatment must continue for many years, because the drugs only kill the larvae and not the adult worms, which can live inside humans for over 10 years,' observes Coffeng. In other words: it is very important that APOC continues its activities, which requires continued support from drug-donating pharmaceutical companies and donor countries, and continued commitment from national governments of the African countries in question and local volunteers. 'The eventual goal of APOC is to completely eradicate river blindness, and this seems to be possible if all stakeholders commit to that goal.'


Story Source:

The above story is based on materials provided by Public Library of Science. Note: Materials may be edited for content and length.


Journal Reference:

  1. Luc E. Coffeng, Wilma A. Stolk, Honorat G. M. Zouré, J. Lennert Veerman, Koffi B. Agblewonu, Michele E. Murdoch, Mounkaila Noma, Grace Fobi, Jan Hendrik Richardus, Donald A. P. Bundy, Dik Habbema, Sake J. de Vlas, Uche V. Amazigo. African Programme for Onchocerciasis Control 1995–2015: Model-Estimated Health Impact and Cost. PLoS Neglected Tropical Diseases, 2013; 7 (1): e2032 DOI: 10.1371/journal.pntd.0002032

Cite This Page:

Public Library of Science. "Fight against river blindness is successful and inexpensive." ScienceDaily. ScienceDaily, 1 February 2013. <www.sciencedaily.com/releases/2013/02/130201090816.htm>.
Public Library of Science. (2013, February 1). Fight against river blindness is successful and inexpensive. ScienceDaily. Retrieved April 25, 2014 from www.sciencedaily.com/releases/2013/02/130201090816.htm
Public Library of Science. "Fight against river blindness is successful and inexpensive." ScienceDaily. www.sciencedaily.com/releases/2013/02/130201090816.htm (accessed April 25, 2014).

Share This



More Health & Medicine News

Friday, April 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Deadly Fungus Killing Bats, Spreading in US

Deadly Fungus Killing Bats, Spreading in US

AP (Apr. 24, 2014) — A disease that has killed more than six million cave-dwelling bats in the United States is on the move and wildlife biologists are worried. White Nose Syndrome, discovered in New York in 2006, has now spread to 25 states. (April 24) Video provided by AP
Powered by NewsLook.com
Companies Ramp Up Wellness to Lower Health Costs

Companies Ramp Up Wellness to Lower Health Costs

AP (Apr. 24, 2014) — That little voice telling you to exercise, get in shape and get healthy is probably coming from your boss. More companies are beefing up wellness programs to try and cut down their health care costs. (April 24) Video provided by AP
Powered by NewsLook.com
Blood From World's Oldest Woman Suggests Life Limit

Blood From World's Oldest Woman Suggests Life Limit

Newsy (Apr. 24, 2014) — Scientists say for the extremely elderly, their stem cells might reach a state of exhaustion. This could limit one's life span. Video provided by Newsy
Powered by NewsLook.com
FDA Wants To Ban Sales Of E-Cigarettes To Minors

FDA Wants To Ban Sales Of E-Cigarettes To Minors

Newsy (Apr. 24, 2014) — The Food and Drug Administration wants to crack down on the use of e-cigarettes, banning the sale of the product to minors. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins